Kunming Pharmaceutical Group announced that net profit attributable to shareholders of listed companies for the first half year of 2026 is estimated to be 400 million yuan to -330 million yuan, a year-on-year decrease of 302%-266% from profit to loss compared with the same period last year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss is expected to be -430 million yuan to -350 million yuan, a decrease of 385%-332% year on year. The pre-loss in performance was mainly due to external factors such as the expansion of the collection of proprietary Chinese medicines, deepening medical insurance fee control, and increased competition for out-of-hospital terminals. Combined with internal adjustments such as optimizing the company's channel inventory and promoting marketing model transformation, the progress of operational improvements fell short of expectations.

Kunming Pharmaceutical Group announced that net profit attributable to shareholders of listed companies for the first half year of 2026 is estimated to be 400 million yuan to -330 million yuan, a year-on-year decrease of 302%-266% from profit to loss compared with the same period last year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss is expected to be -430 million yuan to -350 million yuan, a decrease of 385%-332% year on year. The pre-loss in performance was mainly due to external factors such as the expansion of the collection of proprietary Chinese medicines, deepening medical insurance fee control, and increased competition for out-of-hospital terminals. Combined with internal adjustments such as optimizing the company's channel inventory and promoting marketing model transformation, the progress of operational improvements fell short of expectations.